Form D · Biotechnology
Limelight Bio, Inc.
Philadelphia, PA · CIK 0001785544
Offering snapshot reported Aug 15, 2019 · SEC filing
- Reported sold
- $14M Offering amount: $50M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 16, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 15, 2019 | Initial | $14,002,771 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-346678
Source: Form D, filed Aug 15, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Seth L. Harrison | Director |
| Philip R. Johnson | Director, Executive |
| David Shin | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3401 Grays Ferry Avenue
Philadelphia, PA, 19146
Philadelphia, PA, 19146